Workshop Day - Tuesday, December 3

Workshop A <style="teht;">dsfdfsfsfasfs9.00 - 12.00

Workshop B sdfjslkdflsakjdflskfjsalkkjds 9.00 - 12.00

Progressing Lipid Nanoparticle-Based Delivery of Genome
Editing Therapies

Carlo Zambonelli, Independent LNP Expert

Jeffrey Marshall, Analytical Director, mRNA & gRNA Platforms,
Beam Therapeutics

Navigating a Crowded Market: Target Selection & Portfolio
Strategy

Catherine Symonds, Senior Director, Head of Strategy & New Product Planning, Arbor Biotechnologies

Ryan Leenay, Associate Vice President, Genome Editing, Eli
Lilly

Workshop C <style="teht;">dsfdfsfsfasfs1.00 - 4.00

Workshop D sdfjslkdflsakjdflskfjsalkkjds 1.00 - 4.00

Developing Robust Nonclinical Safety Packages

Ryo Takeuchi, Senior Director, Genome Editing, Excision
BioTherapeutics

Ankit Gupta, Senior Director, Head of Gene Editing,
Affini-T Therapeutics

New FDA Guidance on Platform Technologies: Analysis,
Learnings & Implications for Gene Editing Drug Developers

Claire Levée, Director, Regulatory Affairs, Genetics Medicines, Regeneron Pharmaceuticals

Narin Ahmed, Vice President, Regulatory Science, Tessera
Therapeutics